Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma
复制标题
DOI：
10.1111/j.1365-2141.2012.09067.x
复制
发表时间：
2012-05-01
影响因子：
6.5
通讯作者：
Markovic, Svetomir N.
中科院分区：
文献类型：
--
作者：
Porrata, Luis F.;Ristow, Kay;Markovic, Svetomir N.
结节淋巴细胞为主的霍奇金淋巴瘤(NLPHL)的病理背景由淋巴细胞和组织细胞组成。本研究分析了诊断时外周血淋巴细胞绝对计数/单核细胞绝对计数比率(ALC/AMC-DX)对NLPHL患者生存的影响。从1974年到2010年在梅奥诊所连续跟踪观察的103名NLPHL患者纳入了这项研究。ALC/AMC-DX截断值分析采用受试者工作特性和曲线下面积，ALC/AMC-DX比率采用比例风险模型比较生存率。中位随访期8.9年(范围0.331年)，ALC/AMC-DX=2.1值为最佳生存截断值，曲线下面积为0.82，灵敏度为70%，特异度为84%。在调整国际预后评分后，ALC/AMC-DX仍然是一个独立的预后因素[风险比(HR)，0.33，95%可信区间(CI)，0.150.71%，P<；0.004]；淋巴瘤特异性生存率(HR，0.05；95%CI，0.010.68%，P<；0.002)；无进展生存率(HR，0.30；95%CI，0.140.60%，P<；0.002；进展时间(HR，0.006，95%CI，0.040.30%，P<；0.004)。ALC/AMC-DX是一种低成本、已标准化的生物标志物，可用于预测NLPHL的临床结果。
The pathological background in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) consists of lymphocytes and histocytes. This study analysed the peripheral blood absolute lymphocyte count/absolute monocyte count ratio at diagnosis (ALC/AMC-DX) on the impact of survival in NLPHL. One hundred and three consecutive NLPHL patients that were followed at Mayo Clinic from 1974 to 2010 were included in the study. Receiver operating characteristic and area under the curve were used for ALC/AMC-DX cut-off value analysis and proportional-hazards models were used to compare survival based on the ALC/AMC-DX ratio. With a median follow-up of 8.9 years (range: 0.331 years), an ALC/AMC-DX =2.1 was the best cut-off value for survival with an area under the curve of 0.82, a sensitivity of 70% and specificity of 84%. After adjusting for the International Prognostic Score (IPS), ALC/AMC-DX remained an independent prognostic factor for overall survival [Hazard Ratio (HR), 0.33, 95% confidence interval (CI), 0.150.71%, P < 0.004]; lymphoma-specific survival (HR, 0.05; 95%CI, 0.010.68%, P < 0.002); progression-free survival (HR, 0.30; 95%CI, 0.140.60%, P < 0.006), and time to progression (HR, 0.06, 95%CI, 0.040.30%, P < 0.004). ALC/AMC-DX is a low cost, already standarized, biomarker to predict clinical outcomes in NLPHL.